SEC Form 4 · accession 0001493152-26-038866
Ensysce Biosciences, Inc. · ENSC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bob G Gower
Director
Period of report
Apr 23, 2026
Accepted (ET)
Aug 18, 2026 · 6:06 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001716947
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 23, 2026 | P | 508,614 | $0.484 | A | 516,740 | D | |
| Common Stock | Aug 7, 2026 | P | 400,000 | $0.495 | A | 916,740 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF2 | $0.484 | Apr 23, 2026 | C | 254,307 | A | Apr 23, 2026 | Apr 23, 2028 | Common Stock | 254,307 | 289,836 | D |
Explanation of responses
- F1The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person.
- F2Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169.